# Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

> **NCT03692312** · PHASE2,PHASE3 · COMPLETED · sponsor: **AMO Pharma Limited** · enrollment: 56 (actual)

## Conditions studied

- Congenital Myotonic Dystrophy

## Interventions

- **DRUG:** Tideglusib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03692312
- **Lead sponsor:** AMO Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-03
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692312, "Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03692312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*